Samsung Biologics readies mRNA vaccine drug substance production

By The Science Advisory Board staff writers

Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.

The company's current facility in Songdo, South Korea, is expected to be capable of current good manufacturing practice (cGMP) operations for mRNA vaccine drug substance production by the first half of 2022. As a result, Samsung Biologics will be able to provide end-to-end mRNA vaccine manufacturing services, ranging from bulk substances to aseptic fill/finish including labeling and packaging, as well as cold chain storage, according to the vendor.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?